Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Inventory: 2019-2025

Historic Change in Inventory for Akebia Therapeutics (AKBA) over the last 7 years, with Sep 2025 value amounting to -$6.9 million.

  • Akebia Therapeutics' Change in Inventory fell 1365.87% to -$6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year decrease of 55.17%. This contributed to the annual value of $28.4 million for FY2024, which is 1017.27% up from last year.
  • Per Akebia Therapeutics' latest filing, its Change in Inventory stood at -$6.9 million for Q3 2025, which was down 190.15% from $7.7 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Change in Inventory high stood at $19.2 million for Q1 2021, and its period low was -$24.5 million during Q4 2022.
  • Over the past 3 years, Akebia Therapeutics' median Change in Inventory value was $4.4 million (recorded in 2024), while the average stood at $3.3 million.
  • Over the last 5 years, Akebia Therapeutics' Change in Inventory had its largest YoY gain of 765.20% in 2021, and its largest YoY loss of 4,201.19% in 2021.
  • Akebia Therapeutics' Change in Inventory (Quarterly) stood at -$10.3 million in 2021, then plummeted by 136.59% to -$24.5 million in 2022, then soared by 148.18% to $11.8 million in 2023, then declined by 27.88% to $8.5 million in 2024, then crashed by 1,365.87% to -$6.9 million in 2025.
  • Its Change in Inventory stands at -$6.9 million for Q3 2025, versus $7.7 million for Q2 2025 and $5.0 million for Q1 2025.